MedTrace Logo

Study of PBK_L1704 for the Treatment of Moderate to Severe Acute Pain After Bunionectomy in South Korea

NCT05509868 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 182

Last updated 2026-01-30

No results posted yet for this study

Summary

The primary objective is to evaluate the analgesic efficacy of PBK\_L1704 compared with placebo in patients with moderate to severe acute pain after bunionectomy.

Conditions

  • Acute Pain

Interventions

DRUG

PBK_L1704 0.35mg

The subject will receive PBK\_L1704 0.35mg/ml by PCA

DRUG

PBK_L1704 0.5mg

The subject will receive PBK\_L1704 0.5mg/ml by PCA

DRUG

Placebo

The subject will receive placebo by PCA

Sponsors & Collaborators

  • Pharmbio Korea Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Lee · Seoul Asan Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-25
Primary Completion
2025-02-28
Completion
2025-02-28

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05509868 on ClinicalTrials.gov